Pharmaceuticals

Pulmonary Drugs Market to Reach $70.35 Billion by 2029, Growing at a CAGR of 5.4%

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Pulmonary Drugs Industry In 2025?

The pulmonary drugs market size has shown consistent expansion in recent years. Its value is expected to rise from $54.28 billion in 2024 to $56.98 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. The upward trend observed historically can be credited to factors such as the increasing prevalence of respiratory diseases, the rise in smoking rates, the growing geriatric population, the broadening of healthcare access, and the surge in pollution levels.

The pulmonary drugs market size is anticipated to undergo significant expansion in the forthcoming years. It is projected to increase to $70.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is due to factors such as expanding healthcare infrastructure, an increasing prevalence of cardiovascular disease, the spread of homecare treatments, heightened awareness about pulmonary diseases, and a rising occurrence of asthma. Prominent trends for the forecast period include advancements in technology, AI-driven approaches to drug discovery, the adoption of smart inhalers, nanotechnology-based formulations, and developments in gene therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Pulmonary Drugs Industry?

The growing occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. Respiratory disorders are defined as health conditions impacting the lungs and airways, hindering typical breathing and oxygen exchange. The rise in respiratory disorders stems from the increasing incidence of smoking, which causes lung damage and long-term illnesses. Pulmonary drugs are essential for managing respiratory conditions by enhancing lung performance, decreasing inflammation, and alleviating airway blockages to facilitate easier breathing. As an illustration, data from November 2023, provided by the Bureau of Labor Statistics, a US-based government agency, indicated that the illness rate among private industry employers climbed to 45.2 cases per 10,000 FTE workers in 2022, rising from 37.7 cases in 2021. This increase was primarily linked to a greater incidence of respiratory illnesses, which rose from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalation of respiratory diseases is propelling the expansion of the pulmonary drugs market.

How Is The Pulmonary Drugs Market Classified Into Different Segments?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Which Competitive Trends Are Defining The Pulmonary Drugs Market Structure?

Leading companies operating within the pulmonary drugs market are prioritizing the development of innovative therapies, such as single-inhaler triple therapy (SITT), to improve treatment efficacy, enhance patient adherence, and simplify medication regimens for more effective disease management. Single-inhaler triple therapy (SITT) is a treatment designed to combine three distinct medications in a single inhaler, aiming to more effectively manage chronic respiratory diseases like chronic obstructive pulmonary disease (COPD). For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, launched Trelegy Ellipta, representing India’s first single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary disease (COPD). This therapy incorporates fluticasone furoate, umeclidinium, and vilanterol to boost lung function and decrease the frequency of symptom exacerbations. The advanced Ellipta inhaler ensures accurate dosing and promotes better patient adherence when compared to treatment plans involving multiple inhalers. Given that India has over 100 million COPD patients, this launch aims to streamline treatment and enhance patient outcomes.

Who Are The Prominent Global Companies Shaping The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Do Regional Market Performances Compare Within The Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2025, By The Business Research Company

Pulmonologists Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonologists-global-market-report

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795